© 2015 CTx CRC Pty Ltd
Cancer Therapeutics CRC (CTX) is pleased to announce the appointment of Brett Carter as Chief Executive Officer. Brett will succeed Dr Warwick Tong who has led CTX for the past 6 years and who will continue to provide services to the organisation in an advisory capacity. These changes reflect a transition plan agreed between Dr Tong and the CTX Board to evolve the organisation from a Federally supported Cooperative Research Centre (CRC) into an independent and self-sustainable organisation.
Our job is to discover promising new small molecule drug compounds and advance them through the high risk early phases of drug development.
Our research and development platform spans the full range of technologies required to discover small molecule hits and develop them to clinical candidates. Critically, each of our novel drug discovery projects is underpinned by leading medical researchers with cutting edge expertise in the target biology.
By providing an integrated and coherent pathway for drug discovery and clinical development, CTx is at the forefront of delivering more effective cancer drugs to market.
All our discovery projects are managed and scrutinised by a Project Leaders Group and an independent group of experts as part of our CTx Scientific Advisory Group.